DE602005027213D1 - Neue imidazolidinderivate - Google Patents

Neue imidazolidinderivate

Info

Publication number
DE602005027213D1
DE602005027213D1 DE602005027213T DE602005027213T DE602005027213D1 DE 602005027213 D1 DE602005027213 D1 DE 602005027213D1 DE 602005027213 T DE602005027213 T DE 602005027213T DE 602005027213 T DE602005027213 T DE 602005027213T DE 602005027213 D1 DE602005027213 D1 DE 602005027213D1
Authority
DE
Germany
Prior art keywords
imidazolidine derivatives
new
new imidazolidine
alkyl group
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005027213T
Other languages
English (en)
Inventor
Kazutaka Tachibana
Haruhiko Sato
Masateru Ohta
Mitsuaki Nakamura
Takuya Shiraishi
Ikuhiro Imaoka
Hitoshi Yoshino
Masahiro Nagamuta
Hiromitsu Kawata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE602005027213D1 publication Critical patent/DE602005027213D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
DE602005027213T 2004-08-03 2005-08-03 Neue imidazolidinderivate Active DE602005027213D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004227321 2004-08-03
PCT/JP2005/014195 WO2006013887A1 (ja) 2004-08-03 2005-08-03 新規イミダゾリジン誘導体

Publications (1)

Publication Number Publication Date
DE602005027213D1 true DE602005027213D1 (de) 2011-05-12

Family

ID=35787168

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027213T Active DE602005027213D1 (de) 2004-08-03 2005-08-03 Neue imidazolidinderivate

Country Status (7)

Country Link
US (1) US7803826B2 (de)
EP (1) EP1775289B1 (de)
JP (1) JP4912148B2 (de)
AT (1) ATE503746T1 (de)
DE (1) DE602005027213D1 (de)
TW (1) TW200612920A (de)
WO (1) WO2006013887A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502298T1 (de) * 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
MX2007008334A (es) 2005-01-10 2007-09-11 Acadia Pharm Inc Derivados aminofenilo como moduladores de receptor de androgeno selectivos.
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP5171649B2 (ja) * 2006-02-10 2013-03-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーターとして有用な、二環式イミダゾール又はチアジアゾール複素環
ES2593379T3 (es) 2006-03-27 2016-12-09 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
JP5350217B2 (ja) * 2006-03-29 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールチオヒダントイン化合物
RU2319491C1 (ru) * 2006-07-12 2008-03-20 Бадулин Николай Александрович Противоопухолевая, антибактериальная и антивирусная фармацевтическая композиция (ее варианты)
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
CA2772579C (en) * 2009-09-10 2015-12-08 Youzhi Tong Thioimidazolidinone androgen receptor antagonists and uses thereof
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
AU2012225038B2 (en) 2011-03-10 2016-03-10 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
CN104661658A (zh) 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2017006282A1 (en) * 2015-07-08 2017-01-12 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO2004111012A1 (ja) 2003-06-12 2004-12-23 Chugai Seiyaku Kabushiki Kaisha イミダゾリジン誘導体

Also Published As

Publication number Publication date
US20070249697A1 (en) 2007-10-25
TW200612920A (en) 2006-05-01
ATE503746T1 (de) 2011-04-15
JP4912148B2 (ja) 2012-04-11
EP1775289B1 (de) 2011-03-30
WO2006013887A1 (ja) 2006-02-09
JPWO2006013887A1 (ja) 2008-05-01
EP1775289A4 (de) 2009-09-02
EP1775289A1 (de) 2007-04-18
US7803826B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
ATE503746T1 (de) Neue imidazolidinderivate
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
ATE338461T1 (de) Pyrazolpyrimidinfungizide
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
AR057914A1 (es) Compuestos organicos de azufre y su uso
DK1740584T3 (da) Kondenseret chinolinderivat og anvendelse deraf
WO2008108380A3 (en) Pyrrole compounds
NO20054787D0 (no) Indenderivater som farmasotiske midler
TW200720249A (en) Pyrrolidine compound
TW200744589A (en) Pharmaceutical composition
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
ATE504592T1 (de) Trehaloseverbindung und arzneimittel mit der verbindung
DE602004014727D1 (de) Aminoalkoholderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verwendung davon
FR2894579B1 (fr) Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
HK1130496A1 (en) 3'-ethynylcytidine derivative 3'-
DE60105618D1 (de) Dihydroporphyrinderivate und ihre verwendung
NO20053997D0 (no) Oligosaccharidderivat
AR034313A1 (es) Utilizacion de derivados de piridoindolona para la preparacion de medicamentos
DE602004009306D1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
DE60239491D1 (de) Thiazolidindionderivate und diese enthaltende pharmazeutische zusammensetzung
ATE448198T1 (de) Neue alpha-ketoamidderivate und deren verwendung
MY142362A (en) Pharmaceutical composition for promoting angiogenesis